
    
      First part of the study uses single patient cohorts at the initial dose levels, followed by a
      classic 3+3 design, with enrollment of 3 patients per cohort and expansion to 6 patients in
      the event of a dose-limiting toxicity (DLT).

      The second part of the study consists of expansion cohorts with patients with c-Met
      amplification/mutation of interest.
    
  